Investor Relations

Data as of Nov 16, 2018 1:37 PM EST

PRESS RELEASES

November 15, 2018

Summary Toggle Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit

Highlights potential role of both complement and leukotriene pathways in a therapeutic mouse model of rheumatoid arthritis (RA) NEW YORK and LONDON , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat
November 15, 2018

Summary Toggle Akari Announces Third Quarter 2018 Financial Results and Business Highlights

Four ongoing clinical trial programs Two clinical programs expected to report initial data in first quarter 2019 Long-term clinical study continues to yield encouraging safety data NEW YORK and LONDON , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical
September 30, 2018

Summary Toggle Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies. Data Supports Akari’s Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous

Coversin, a first-in-class combined complement C5 and leukotriene B4 (LTB4) inhibitor, is currently being developed to treat four orphan diseases: Thrombotic microangiopathies (TMAs) Bullous pemphigoid (BP) Atypical keratoconjunctivits (AKC) Paroxysmal nocturnal hemoglobinuriua (PNH) All four

Company Presentation – October 2018

October 1, 2018

Company Presentation – October 2018 380.6 KB
EHA 2018 Poster

June 15, 2018

EHA 2018 Poster 467.9 KB
ARVO 2018 Poster

May 16, 2018

ARVO 2018 Poster 378.7 KB